Axsome Therapeutics AXSM Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's total current liabilities?
- Axsome Therapeutics (AXSM) reported total current liabilities of $439.21M in Q1 2026.
- How has Axsome Therapeutics's total current liabilities changed year-over-year?
- Axsome Therapeutics's total current liabilities increased by 80.1% year-over-year, from $243.91M to $439.21M.
- What is the long-term trend for Axsome Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Axsome Therapeutics's total current liabilities has grown at a 74.5% compound annual growth rate (CAGR), from $23.44M to $378.84M.
- What does total current liabilities mean?
- The total amount of debt and obligations due within one year.
- How do you interpret total current liabilities?
- An increase relative to current assets may signal liquidity risk, while a decrease generally improves the company's short-term financial health.
- How does total current liabilities compare across companies?
- Standard metric used to calculate the current ratio across all industries.